Some factors commonly used to explain poor operating performance do not prevent many hospitals from being highly profitable. For example, Truven Health AnalyticsTM has found that rates of uncompensated care, drug expense, and other factors do not seem to differ between unprofitable and very profitable hospitals. But factors such as Medicaid utilization rates and poor reimbursement rates do appear to impact the least profitable hospitals. One controllable factor that appears to be significant is labor productivity, with the most profitable hospitals posting the lowest labor expense per patient.
Eli Lilly Japan has numerous large and valuable brands, including
Humalog and Trulicity. When launching new products, Eli Lilly wants
customer—health care providers (HCP) and patients—to have the best
possible experiences. This means delivering products that go “beyond
the pill.” By embedding its drugs into holistic offerings while leveraging
digital channels, real-world evidence, Artificial Intelligence (AI), and
automation, Eli Lilly Japan aims to transform customer engagement,
leading to competitive advantage and improved patients’ health
A recent Forbes article called robotic process automation (RPA) “a gateway drug to artificial intelligence (AI)”. In other words, RPA, provides organizations with a low barrier to entry into the AI world along with many of its benefits. Call it dipping a toe in the AI waters.
What’s clear is RPA is on a tipping point. But will this growth continue? In this e-book we explore 7 predictions for the RPA market in 2019 from the market-leading platform, Automation Anywhere.
An integrated launch plan was just the start for helping to transform a research organization into a commercial entity. A successful commercial launch of an FDA-approved specialty drug included project management support to a cross-functional client team and development of a dashboard tool to track each function’s progress.
Collaborative helped a research company transitioning to commercialization identify critical timelines, tasks, milestones and resources required to bring a new drug to market. As part of the project, leaders were given the information and tools they needed and the business began building the strong foundation necessary for a successful launch.
To the casual observer, aircraft manufacturer Airbus UK and pharmaceutical giant GlaxoSmithKline (GSK) wouldn't appear to share a lot of common ground. Some would say that the worlds of building airplanes and producing the next blockbuster wonder-drug are light years apart. A closer look shows that these two organizations are more similar than one might initially think.
Good Manufacturing Practices (GMP) violations have become the new healthcare fraud as the Department of Justice (DOJ) tests out new legal theories under the False Claims Act (FCA). The Food and Drug Administration (FDA) has dusted off its regulatory authority to prosecute GMP violations.
In this webinar, experts discuss how data and analytics can be applied to improve health program outcomes and how social determinants of health affect risk. It includes a case study on how the application of advanced analytic methods helped to decipher the impact of high-priced specialty drugs on the overall population. The experts also address how artificial intelligence can drive better decision-making, improve population health and cut costs.
Top 5 Factors Every Bio-Tech and Pharmaceutical Company Must Keep in Mind.
Successfully launching a product in the U.S. requires a balance across commercial strategy, government programs, and contracting operations. While the market holds significant opportunity, there are also complexities that need to be considered prior to launch.
To prepare for the launch of your drug in the U.S. market, download a copy of Navigating the U.S. Government Market to help your organization remain compliant with government operational and pricing requirements.
Published By: DrFirst
Published Date: Mar 13, 2015
For hospitals, medication reconciliation is critical to quality patient care. Obtaining a complete and accurate list of the patient’s medications sets the cornerstone for good patient care during the hospital stay, informing doctors about treatments in progress, and arming them to prevent potentially harmful drug interactions.
Social Media Risks and Benefits for the Pharmaceuticals Industry
Drug makers are just beginning to realize how social networks can improve business processes. Social media helps your organization share information and exchange ideas with your customers quickly, but doing so can involve considerable risk. That’s because social media is subject to the scrutiny of regulators, legislators, and litigators. So, what seems like a spoon full of sugar is often a tough pill to swallow when you consider regulatory requirements from agencies like the FDA. On top of that, increasing litigation has made it a business requirement to consider solutions that help bring down skyrocketing legal costs. Not having technology in place to help manage these requirements and increasing risks, or doing so without careful planning, can be a costly mistake.
Read this paper to gain an understanding of:
What the regulatory landscape of the pharmaceuticals industry looks like
What concerns you should be aware of f
Published By: MarkLogic
Published Date: Mar 29, 2018
It’s your golden opportunity: Rapidly integrate and harmonize data silos. Enhance drug discovery. Achieve faster time to insight. Get to market faster — all with less cost than you think.
Explore how Life Sciences organizations can accelerate Real World Evidence (RWE) in a comprehensive and cost efficient manner. Download this white paper to learn about challenges, solutions and most importantly — how to equip your organization for success.
Published By: MarkLogic
Published Date: May 07, 2018
Learn how Life Sciences organizations can accelerate Real World Evidence by achieving faster time to insight with a metadata-driven, semantically enriched operational platform.
Real World Evidence (RWE) is today’s big data challenge in Life Sciences. Medical records, registries, consultation reports, insurance claims, pharmacy data, social media, and patient surveys all contain valuable insights that Life Sciences organizations need to ascertain and prove the safety, efficacy, and value of their drugs and medical devices.
Learn how Life Sciences organizations can accelerate RWE with a metadata-driven, semantically enriched operational platform that enables them to:
• Unify, harmonize and ensure governance of information from diverse data sources
• Transform information into evidence that proves product efficacy and safety
• Identify data patterns, connections, and relationships for faster time to insight
Clinical decision support solutions are critical to delivering quality care, but how do you know which tools are most effective? In this video, David Bordewyk, national director for clinical solutions at Truven Health, explains five considerations for evaluating current or prospective solutions. First, the tool should provide evidence-based, actionable recommendations. Learn how to determine whether that’s the case, as well as how to identify tools that provide comprehensive information, information that’s consistent, and information that’s easy to find and access. Additionally, the tool should provide access from multiple types of devices and the vendor should offer ongoing user training and support.
The intent of this technical bulletin is to summarize and clarify the respiratory protection guidance from both USP and NIOSH for workers who handle hazardous drugs in the healthcare environment. Download now to learn more.
Published By: Medidata
Published Date: Nov 10, 2017
Founded by physicians committed to advancing medical science, Worldwide Clinical Trials is out to change how the world experiences CROs. From early phase and bioanalytical sciences through late phase and post-approval, they provide full-service drug development services across a range of therapeutic areas, including neuroscience, cardiovascular diseases, immune-mediated inflammatory disorders (IMID) and rare diseases.
Published By: Siemens
Published Date: Jun 06, 2014
In implementing its patient portal, Main Line Health’s goal was to create a one-stop portal for the entire health system. With four acute-care hospitals, several outpatient facilities, a physical medicine and rehab hospital and a drug and alcohol treatment center, Main Line Health needed a solution that could quickly relay information from multiple points of care to thousands of patients.
In the age of evolving shopper expectations and technology advancements, the global retail industry is in the midst of a profound shift in retail operations. To gain a deeper understanding of retailers’ focus, concerns and investment plans, Zebra conducted a global research study across a wide spectrum of retail segments, including: specialty stores, department stores, apparel merchants, supermarkets, electronics, home improvement and drugstore chains. The results of this study are shared in this 2017 Retail Vision Study.
Up to 5% of all hospitalized patients are affected by ADEs. Implementing a comprehensive Barcode Medication Administration (BCMA) program can help, reducing medication errors up to 80%.
In this white paper Zebra Technologies uncovers best practices for adopting Barcode Medication Administration, including:
The importance of building a multidisciplinary implementation team
The role of efficient, well-defined workflows
How accurate data management and reporting are essential to ongoing BCMA success
Unique serial numbers must now be applied to individual bottles of drugs and the cases that carry them in California, due to new tracking requirements. Read this white paper to learn how the IBM Serialization Pilot Kit with TAGSYS RFID is helping companies achieve compliance in less than a year.
Physicians and their patients, medical policy makers and licensing boards, pharmaceutical companies and pharmacies all must work together to stem the opioid epidemic and achieve the fundamental objectives of reducing addiction and deaths. With so many players and data sources, today’s information is partial, fragmented, and often not actionable. We don’t have the data to understand what’s happening, to adjust policy, and to motivate physicians and patients to change their behaviors.
Better data and analytics can help develop better treatment protocols, both for pain in the first place and for remediation when patients are becoming dependent on the drugs.
Need to implement a pre-employment screening solution for your organization or want to evaluate your current program? Download this free whitepaper to receive a clear explanation of what you should consider to help mitigate risk.